Literature DB >> 28053143

Arl4c is a key regulator of tubulogenesis and tumourigenesis as a target gene of Wnt-β-catenin and growth factor-Ras signalling.

Shinji Matsumoto1, Shinsuke Fujii2,3, Akira Kikuchi4.   

Abstract

Epithelial tubular morphogenesis (tubulogenesis) is a fundamental morphogenetic process of many epithelial organs. In this developmental process, epithelial cells migrate, proliferate, polarize and differentiate towards surrounding mesenchymal tissue to form tubule structures. Although epithelial tissue structures are basically stable in the postnatal period, epithelial cells regain highly proliferative and invasive potentials within mesenchymal tissue during tumour formation (tumourigenesis). Therefore, there must be a common molecular basis orchestrating the cellular behaviours involved in both tubulogenesis and tumourigenesis. ADP-ribosylation factor (Arf)-like protein 4c (Arl4c), which belongs to the small GTP-binding protein family, is expressed by the simultaneous activation of Wnt-β-catenin and growth factor-Ras-mitogen-activated protein kinase signalling, was identified as an essential regulator of tubulogenesis. Arl4c expression was also involved in the tumour formation of colorectal and lung cancers. In this review, we focus on Arl4c as a novel Wnt signal target molecule that links epithelial tubulogenesis to tumourigenesis.
© The Authors 2016. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.

Entities:  

Keywords:  Arl4c; Wnt; growth factor; tubulogenesis; tumourigenesis

Mesh:

Substances:

Year:  2016        PMID: 28053143     DOI: 10.1093/jb/mvw069

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  14 in total

1.  CRL5-dependent regulation of the small GTPases ARL4C and ARF6 controls hippocampal morphogenesis.

Authors:  Jisoo S Han; Keiko Hino; Wenzhe Li; Raenier V Reyes; Cesar P Canales; Adam M Miltner; Yasmin Haddadi; Junqing Sun; Chao-Yin Chen; Anna La Torre; Sergi Simó
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-01       Impact factor: 11.205

2.  Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion.

Authors:  Akikazu Harada; Shinji Matsumoto; Yoshiaki Yasumizu; Kensaku Shojima; Toshiyuki Akama; Hidetoshi Eguchi; Akira Kikuchi
Journal:  Elife       Date:  2021-09-30       Impact factor: 8.140

3.  ARL4C Regulates the Progression of Clear Cell Renal Cell Carcinoma by Affecting the Wnt/β-Catenin Signaling Pathway.

Authors:  Peizhi Zhang; Yingkun Xu; Shaoan Chen; Zicheng Wang; Leizuo Zhao; Chen Chen; Weiting Kang; Rongyu Han; Jiechuan Qiu; Qingliang Wang; Han Gao; Guangzhen Wu; Qinghua Xia
Journal:  J Oncol       Date:  2022-06-21       Impact factor: 4.501

4.  Interferon tau-dependent and independent effects of the bovine conceptus on the endometrial transcriptome†.

Authors:  Daniel J Mathew; José M Sánchez; Claudia Passaro; Gilles Charpigny; Susanta K Behura; Thomas E Spencer; Patrick Lonergan
Journal:  Biol Reprod       Date:  2019-02-01       Impact factor: 4.285

Review 5.  RNA-based therapies: A cog in the wheel of lung cancer defense.

Authors:  Parvez Khan; Jawed Akhtar Siddiqui; Imayavaramban Lakshmanan; Apar Kishor Ganti; Ravi Salgia; Maneesh Jain; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Mol Cancer       Date:  2021-03-19       Impact factor: 27.401

6.  Analysis of the long non-coding RNA LINC01614 in non-small cell lung cancer.

Authors:  Yan Sun; Chunhua Ling
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 7.  Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review.

Authors:  Tsukuru Amano; Tokuhiro Chano; Fumi Yoshino; Fuminori Kimura; Takashi Murakami
Journal:  Healthcare (Basel)       Date:  2019-07-30

8.  ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.

Authors:  Kenji Kimura; Shinji Matsumoto; Takeshi Harada; Eiichi Morii; Izumi Nagatomo; Yasushi Shintani; Akira Kikuchi
Journal:  Cancer Sci       Date:  2020-02-22       Impact factor: 6.716

Review 9.  Regulatory Mechanisms of the Wnt/β-Catenin Pathway in Diabetic Cutaneous Ulcers.

Authors:  Han Zhang; Xuqiang Nie; Xiujun Shi; Jiufeng Zhao; Yu Chen; Qiuyang Yao; Chengxin Sun; Jianwen Yang
Journal:  Front Pharmacol       Date:  2018-10-17       Impact factor: 5.810

10.  The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/β-Catenin Signaling Pathway.

Authors:  Jinrong Liao; Zeng Chen; Zongyang Yu; Tao Huang; Dan Hu; Ying Su; Zhiyong He; Changyan Zou; Lurong Zhang; Xiandong Lin
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.